Part A: Phase IB, Single Site, Dose-Escalation of SCD-101 and Part B: Randomized, Double-Blind, Placebo-Controlled Crossover of SCD-101 in Adults With Homozygous Sickle Cell Disease or S/Beta 0 Thalassemia.
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2017
At a glance
- Drugs SCD 101 (Primary)
- Indications Beta-thalassaemia; Sickle cell anaemia
- Focus Adverse reactions
- Sponsors Invenux LLC
- 11 Apr 2017 Planned number of patients changed from 24 to 60.
- 11 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
- 11 Apr 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History